NCT05208125View on ClinicalTrials.gov

A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines ChAdOx1.HTI and MVA.HTI With Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted With MPLA Liposomes in ART-Suppressed HIV-1 Positive Individuals

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 30, 2022

Primary Completion Date

March 30, 2022

Study Completion Date

December 18, 2023

Conditions
HIV Infection
Interventions
BIOLOGICAL

ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS).

Intramuscular administration of 1 x ChAdOx1.HTI (5x1010 Vp), 3 x ConM SOSIP.v7 (100μg) adjuvanted with MPLA liposomes (500μg), and 1 x MVA.HTI (2x108pfu)

OTHER

Normal saline solution

Intramuscular administration of normal saline solution

Trial Locations (1)

08916

Germans Trias i Pujol Hospital, Badalona

All Listed Sponsors
collaborator

José Moltó Marhuenda, PhD, MD

UNKNOWN

collaborator

Beatriz Mothe Pujadas PhD,MD

UNKNOWN

collaborator

Susana Benet Garrabé, PhD,MD

UNKNOWN

collaborator

Lucía Bailón Álvarez, MD

UNKNOWN

lead

IrsiCaixa

OTHER